Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

NCT01225887 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT01225887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01225887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
January 31, 2016
Enrollment
37 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial clear cell adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial serous adenocarcinoma, endometrial squamous cell carcinoma, endometrial transitional cell carcinoma, endometrial undifferentiated carcinoma, malignant uterine corpus mixed epithelial and mesenchymal neoplasm, recurrent uterine corpus carcinoma